Medication Management in Chronic Kidney Disease

Introduction to Medication Management

Medication management is crucial in patients with Chronic Kidney Disease (CKD) to minimize the risk of adverse events and optimize treatment outcomes 1, 2

For patients with CKD stage 3b (eGFR 30-44 mL/min/1.73m²), the maximum dose of metformin should be reduced to 1000 mg per day, as recommended by the Kidney International guideline 1
Metformin should be discontinued when eGFR falls below 30 mL/min/1.73m² (CKD Stage 4-5) due to increased risk of lactic acidosis, as suggested by the American Journal of Kidney Diseases 3, 1
Metformin offers reduced mortality compared to other glucose-lowering therapies in patients with eGFRs of 30-60 mL/min/1.73m², with significant cardiovascular benefits, particularly in overweight patients with type 2 diabetes 2

For patients with eGFR ≥20 mL/min/1.73m², SGLT2 inhibitors are recommended as an alternative therapy, with GLP-1 receptor agonists offering another option with cardiovascular benefits 1, 2
Glipizide is the preferred sulfonylurea for patients with CKD, as it does not have active metabolites and does not increase hypoglycemia risk, according to the American Journal of Kidney Diseases 4
Sitagliptin with dose adjustment may be considered as an alternative therapy 2

Monitoring frequency should be increased to every 3-6 months for patients with eGFR <60 mL/min/1.73m², including checking eGFR and monitoring renal function 1
Lactate levels should be measured if clinical concerns arise, particularly in patients with conditions that increase the risk of lactic acidosis, such as acute kidney injury, hypoxemia, sepsis, alcohol abuse, liver failure, myocardial infarction, and shock or hypoperfusion states 5, 2
Metformin should be temporarily discontinued during acute illness, risk of acute kidney injury, iodinated contrast procedures, and major surgery, or when the patient experiences dehydration, vomiting, diarrhea, fever with reduced oral intake, or any condition that may worsen renal function 1

The risk of lactic acidosis is minimal when appropriate precautions are taken, with no cases reported in a Cochrane meta-analysis 2
Metformin has a low risk of hypoglycemia compared to sulfonylureas, according to the American Journal of Kidney Diseases 4